Navidea Biopharmaceuticals (NAVB) Stock Price, News & Analysis

Company Overview

Navidea Biopharmaceuticals, Inc. is a clinical‐stage biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and radiopharmaceutical therapeutics designed to guide disease management. The company’s lead product, Lymphoseek® (technetium Tc 99m tilmanocept), is an FDA‐approved lymphatic mapping agent used during surgical procedures to identify sentinel lymph nodes in breast cancer and melanoma patients. Navidea’s platform leverages proprietary targeting molecules that bind to specific biomarkers, enabling high‐resolution imaging and targeted delivery of therapeutic radioisotopes.

In addition to its marketed product, Navidea maintains an active pipeline of investigational radiopharmaceuticals in oncology, immunology and neurology. The company is advancing candidates aimed at improving early detection of Alzheimer’s disease through tau PET imaging, as well as investigational therapies for inflammatory and infectious diseases. These programs employ site‐specific binding technologies to concentrate diagnostic or therapeutic payloads at disease sites, minimizing off‐target exposure and enhancing clinical utility.

Originally incorporated in Delaware in the mid‐1990s under a different name, the company rebranded as Navidea Biopharmaceuticals in 2013 following its acquisition of lymphatic mapping assets from Cardinal Health. Headquartered in Dublin, Ohio, Navidea operates research and development facilities in the United States and collaborates with academic and industry partners to support global clinical trials and pursue regulatory approvals outside North America.

Under the leadership of President and Chief Executive Officer Michael H. Koren, Navidea continues to expand its manufacturing capabilities and strengthen its intellectual property portfolio. The company’s strategic focus on precision imaging and targeted radiotherapeutics reflects a commitment to advance patient care through innovative diagnostic tools and novel treatment modalities.

Key Stats

• Today's Range: $0.0002 to $0.0002
• 50-Day Range: N/A
• 52-Week Range: $0.00 to $0.13
• Volume: N/A
• Average Volume: 8,776 shs
• Market Capitalization: $20.02 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NAVB Stock Analysis - Frequently Asked Questions

How have NAVB shares performed this year?

Navidea Biopharmaceuticals' stock was trading at $0.0001 at the beginning of the year. Since then, NAVB shares have increased by 100.0% and is now trading at $0.0002.

How were Navidea Biopharmaceuticals' earnings last quarter?

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) announced its earnings results on Wednesday, November, 10th. The company reported ($0.08) earnings per share for the quarter, topping analysts' consensus estimates of ($0.11) by $0.03. The business had revenue of $0.10 million for the quarter, compared to analysts' expectations of $0.60 million.

How do I buy shares of Navidea Biopharmaceuticals?

Shares of NAVB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Navidea Biopharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Navidea Biopharmaceuticals investors own include Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), CorMedix (CRMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), Advanced Micro Devices (AMD) and Catalyst Pharmaceuticals (CPRX).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 7/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Diagnostic substances
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:NAVB
• CIK: 810509
• Web: www.navidea.com
• Phone: 614-793-7500
• Fax: 614-793-7522
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $8.13 thousand
• Price / Sales: 2.46
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 100,084,000
• Free Float: 56,367,000
• Market Cap: $20.02 thousand
• Optionable: Optionable
• Beta: 1.75